Recent advances in cancer drug development: Targeting induced myeloid cell leukemia-1 (mcl-1) differentiation protein

Mohammad Abid, Yogesh A. Sonawane, Jacob I. Contreras, Sandeep Rana, Amarnath Natarajan

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Anti-apoptotic members of the Bcl-2 family of proteins are upregulated in a majority of cancers and are potential therapeutic targets. Fragment-based design led to the development of clinical candidates that target Bcl-xL/Bcl-2. Although these BclxL/ Bcl-2 inhibitors showed promise in pre-clinical studies, resistance to several Bcl-xL inhibitors was observed, when used alone. This is attributed to the over-expression of Mcl-1, another member of the Bcl-2 family of proteins. Indeed, Mcl-1 is highly amplified in numerous cancers, suggesting that it may contribute to malignant cell growth and evasion of apoptosis. Therefore, significant efforts have been made toward the development of direct Mcl-1 inhibitors for cancer therapy. Methods: Following an extensive search of peer-reviewed articles on the development of Mcl-1-selective inhibitors, the literature retrieved is chronologically arranged and discussed in this review article. Results: We have included 147 articles in this review; including articles that describe the development of stapled peptides with improved binding affinity as Mcl-1-selective BH3 mimetics, those describing fragment-based and structure-based design of small molecule Mcl-1 inhibitors by various research groups, and those detailing the use of natural products and their derivatives as potential Mcl-1 inhibitors. Conclusion: The therapeutic potential of targeting the Mcl-1 protein for cancer drug discovery is vast. Stapling BH3 peptides, as well as the development of small molecule inhibitors as BH3 mimetics, are viable strategies to develop selective Mcl-1 inhibitors. With no clinically approved candidate in hand, additional modes of perturbing the biological function of this protein will aid drug discovery efforts.

Original languageEnglish (US)
Pages (from-to)4488-4514
Number of pages27
JournalCurrent medicinal chemistry
Volume24
Issue number40
DOIs
StatePublished - Jan 1 2017

Fingerprint

Myeloid Leukemia
Myeloid Cells
Drug Delivery Systems
Drug Discovery
Pharmaceutical Preparations
Neoplasms
Proteins
Molecules
Cell growth
Biological Products
Therapeutics
Hand
Apoptosis
Derivatives
Peptides
Growth
Research

Keywords

  • Apoptosis
  • BH3-mimetics
  • Bcl-2
  • Bcl-xL
  • Cancer
  • Mcl-1
  • Small molecule inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Recent advances in cancer drug development : Targeting induced myeloid cell leukemia-1 (mcl-1) differentiation protein. / Abid, Mohammad; Sonawane, Yogesh A.; Contreras, Jacob I.; Rana, Sandeep; Natarajan, Amarnath.

In: Current medicinal chemistry, Vol. 24, No. 40, 01.01.2017, p. 4488-4514.

Research output: Contribution to journalReview article

Abid, Mohammad ; Sonawane, Yogesh A. ; Contreras, Jacob I. ; Rana, Sandeep ; Natarajan, Amarnath. / Recent advances in cancer drug development : Targeting induced myeloid cell leukemia-1 (mcl-1) differentiation protein. In: Current medicinal chemistry. 2017 ; Vol. 24, No. 40. pp. 4488-4514.
@article{c4d0bbf1e0f64cabb83873be1d7178bc,
title = "Recent advances in cancer drug development: Targeting induced myeloid cell leukemia-1 (mcl-1) differentiation protein",
abstract = "Background: Anti-apoptotic members of the Bcl-2 family of proteins are upregulated in a majority of cancers and are potential therapeutic targets. Fragment-based design led to the development of clinical candidates that target Bcl-xL/Bcl-2. Although these BclxL/ Bcl-2 inhibitors showed promise in pre-clinical studies, resistance to several Bcl-xL inhibitors was observed, when used alone. This is attributed to the over-expression of Mcl-1, another member of the Bcl-2 family of proteins. Indeed, Mcl-1 is highly amplified in numerous cancers, suggesting that it may contribute to malignant cell growth and evasion of apoptosis. Therefore, significant efforts have been made toward the development of direct Mcl-1 inhibitors for cancer therapy. Methods: Following an extensive search of peer-reviewed articles on the development of Mcl-1-selective inhibitors, the literature retrieved is chronologically arranged and discussed in this review article. Results: We have included 147 articles in this review; including articles that describe the development of stapled peptides with improved binding affinity as Mcl-1-selective BH3 mimetics, those describing fragment-based and structure-based design of small molecule Mcl-1 inhibitors by various research groups, and those detailing the use of natural products and their derivatives as potential Mcl-1 inhibitors. Conclusion: The therapeutic potential of targeting the Mcl-1 protein for cancer drug discovery is vast. Stapling BH3 peptides, as well as the development of small molecule inhibitors as BH3 mimetics, are viable strategies to develop selective Mcl-1 inhibitors. With no clinically approved candidate in hand, additional modes of perturbing the biological function of this protein will aid drug discovery efforts.",
keywords = "Apoptosis, BH3-mimetics, Bcl-2, Bcl-xL, Cancer, Mcl-1, Small molecule inhibitors",
author = "Mohammad Abid and Sonawane, {Yogesh A.} and Contreras, {Jacob I.} and Sandeep Rana and Amarnath Natarajan",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/0929867324666170912092659",
language = "English (US)",
volume = "24",
pages = "4488--4514",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "40",

}

TY - JOUR

T1 - Recent advances in cancer drug development

T2 - Targeting induced myeloid cell leukemia-1 (mcl-1) differentiation protein

AU - Abid, Mohammad

AU - Sonawane, Yogesh A.

AU - Contreras, Jacob I.

AU - Rana, Sandeep

AU - Natarajan, Amarnath

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Anti-apoptotic members of the Bcl-2 family of proteins are upregulated in a majority of cancers and are potential therapeutic targets. Fragment-based design led to the development of clinical candidates that target Bcl-xL/Bcl-2. Although these BclxL/ Bcl-2 inhibitors showed promise in pre-clinical studies, resistance to several Bcl-xL inhibitors was observed, when used alone. This is attributed to the over-expression of Mcl-1, another member of the Bcl-2 family of proteins. Indeed, Mcl-1 is highly amplified in numerous cancers, suggesting that it may contribute to malignant cell growth and evasion of apoptosis. Therefore, significant efforts have been made toward the development of direct Mcl-1 inhibitors for cancer therapy. Methods: Following an extensive search of peer-reviewed articles on the development of Mcl-1-selective inhibitors, the literature retrieved is chronologically arranged and discussed in this review article. Results: We have included 147 articles in this review; including articles that describe the development of stapled peptides with improved binding affinity as Mcl-1-selective BH3 mimetics, those describing fragment-based and structure-based design of small molecule Mcl-1 inhibitors by various research groups, and those detailing the use of natural products and their derivatives as potential Mcl-1 inhibitors. Conclusion: The therapeutic potential of targeting the Mcl-1 protein for cancer drug discovery is vast. Stapling BH3 peptides, as well as the development of small molecule inhibitors as BH3 mimetics, are viable strategies to develop selective Mcl-1 inhibitors. With no clinically approved candidate in hand, additional modes of perturbing the biological function of this protein will aid drug discovery efforts.

AB - Background: Anti-apoptotic members of the Bcl-2 family of proteins are upregulated in a majority of cancers and are potential therapeutic targets. Fragment-based design led to the development of clinical candidates that target Bcl-xL/Bcl-2. Although these BclxL/ Bcl-2 inhibitors showed promise in pre-clinical studies, resistance to several Bcl-xL inhibitors was observed, when used alone. This is attributed to the over-expression of Mcl-1, another member of the Bcl-2 family of proteins. Indeed, Mcl-1 is highly amplified in numerous cancers, suggesting that it may contribute to malignant cell growth and evasion of apoptosis. Therefore, significant efforts have been made toward the development of direct Mcl-1 inhibitors for cancer therapy. Methods: Following an extensive search of peer-reviewed articles on the development of Mcl-1-selective inhibitors, the literature retrieved is chronologically arranged and discussed in this review article. Results: We have included 147 articles in this review; including articles that describe the development of stapled peptides with improved binding affinity as Mcl-1-selective BH3 mimetics, those describing fragment-based and structure-based design of small molecule Mcl-1 inhibitors by various research groups, and those detailing the use of natural products and their derivatives as potential Mcl-1 inhibitors. Conclusion: The therapeutic potential of targeting the Mcl-1 protein for cancer drug discovery is vast. Stapling BH3 peptides, as well as the development of small molecule inhibitors as BH3 mimetics, are viable strategies to develop selective Mcl-1 inhibitors. With no clinically approved candidate in hand, additional modes of perturbing the biological function of this protein will aid drug discovery efforts.

KW - Apoptosis

KW - BH3-mimetics

KW - Bcl-2

KW - Bcl-xL

KW - Cancer

KW - Mcl-1

KW - Small molecule inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85041392172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041392172&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170912092659

DO - 10.2174/0929867324666170912092659

M3 - Review article

C2 - 28901269

AN - SCOPUS:85041392172

VL - 24

SP - 4488

EP - 4514

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 40

ER -